GID, a real estate investor, operator, developer and fiduciary that has been around for the last six decades, launched a new platform at the end of October called GID Residential Partners, which will ...

Please note that the posts on The Blogs are contributed by third parties. The opinions, facts and any media content in them are presented solely by the authors, and neither The Times of Israel nor its ...

Global fitness brand FS8 will soon open its first New York City studio on Manhattan’s Upper West Side. The asking rent was unclear, but a report from CBRE found retail rents near the Upper West Side ...

Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...

A couple hundred Denver voters living near Broadway voted in favor of forming the city’s sixth general improvement district (GID), as more residents and business owners ask for additional, ...

GID is dedicating resources to boost its multifamily developments. The firm has launched GID Residential Partners, a business platform within the existing company. It will focus on advancing the ...

NEW YORK--(BUSINESS WIRE)--GID, a vertically-integrated real estate owner, operator, developer and investor with $31.5 billion in assets under management, today announced the expansion of its ...

Some Denver area residents first reached out to CBS Colorado to share their concern about the possibility of a general improvement district at the beginning of August. Since then, the community ...

In many a school auditorium, a theater kid could be spotted sitting cross-legged with a peanut butter and jelly sandwich, surrounded by peers who had just belted their way through the entire Hamilton ...

Any hobbyist can produce videos and upload them on YouTube to share with the world. But as a small-business owner, you also can produce tutorials to make money, which can be an effective source of ...

Suggested remit: To appraise the clinical and cost effectiveness of tafasitamab plus lenalidomide and rituximab within its marketing authorisation for relapsed or refractory follicular lympho-ma after ...